Summary
Pfizer Inc. (PFE) has filed an 8-K report detailing updated financial guidance. The company announced revised full-year 2025 revenue guidance and provided its full-year 2026 guidance, while reaffirming all other components of its 2025 financial outlook. This update is being communicated to investors via a press release filed as an exhibit to this report. Investors should pay close attention to the specifics of the revenue revision for 2025 and the outlook for 2026 as provided in the accompanying press release. While other 2025 guidance components remain unchanged, the revenue adjustments could signal shifts in market dynamics or product performance. The 2026 guidance will offer a forward-looking perspective on Pfizer's expected financial trajectory.
Key Highlights
- 1Pfizer issued revised full-year 2025 revenue guidance.
- 2Pfizer provided its full-year 2026 financial guidance.
- 3All other components of Pfizer's full-year 2025 financial guidance were reaffirmed.
- 4The information was disclosed via a press release dated December 16, 2025.
- 5The press release is furnished as Exhibit 99.1 to the 8-K filing.
- 6This filing is for informational purposes under Regulation FD.
- 7Includes the Cover Page Interactive Data File in XBRL format.